JP2020528768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528768A5 JP2020528768A5 JP2020527852A JP2020527852A JP2020528768A5 JP 2020528768 A5 JP2020528768 A5 JP 2020528768A5 JP 2020527852 A JP2020527852 A JP 2020527852A JP 2020527852 A JP2020527852 A JP 2020527852A JP 2020528768 A5 JP2020528768 A5 JP 2020528768A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023123773A JP2023153911A (ja) | 2017-07-27 | 2023-07-28 | 抗ｔｉｇｉｔ抗体 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762606159P | 2017-07-27 | 2017-07-27 | |
| US62/606,159 | 2017-07-27 | ||
| BE2017/5535A BE1025333B1 (fr) | 2017-07-27 | 2017-07-31 | Anticorps anti-tigit |
| EP17184102.6 | 2017-07-31 | ||
| BE2017/5535 | 2017-07-31 | ||
| EP17184102 | 2017-07-31 | ||
| US201862660640P | 2018-04-20 | 2018-04-20 | |
| US62/660,640 | 2018-04-20 | ||
| PCT/US2018/043968 WO2019023504A1 (en) | 2017-07-27 | 2018-07-26 | ANTI-TIGIT ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023123773A Division JP2023153911A (ja) | 2017-07-27 | 2023-07-28 | 抗ｔｉｇｉｔ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020528768A JP2020528768A (ja) | 2020-10-01 |
| JP2020528768A5 true JP2020528768A5 (enExample) | 2021-09-02 |
| JP7366897B2 JP7366897B2 (ja) | 2023-10-23 |
Family
ID=65896429
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020527852A Active JP7366897B2 (ja) | 2017-07-27 | 2018-07-26 | 抗ｔｉｇｉｔ抗体 |
| JP2023123773A Pending JP2023153911A (ja) | 2017-07-27 | 2023-07-28 | 抗ｔｉｇｉｔ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023123773A Pending JP2023153911A (ja) | 2017-07-27 | 2023-07-28 | 抗ｔｉｇｉｔ抗体 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20200407445A1 (enExample) |
| EP (2) | EP3719040A1 (enExample) |
| JP (2) | JP7366897B2 (enExample) |
| KR (1) | KR102731476B1 (enExample) |
| CN (2) | CN110997720B (enExample) |
| AR (1) | AR112768A1 (enExample) |
| AU (1) | AU2018306463B2 (enExample) |
| BR (1) | BR112020001499A2 (enExample) |
| CA (1) | CA3070791A1 (enExample) |
| ES (1) | ES2812236T3 (enExample) |
| IL (1) | IL272227B2 (enExample) |
| MX (2) | MX2020000960A (enExample) |
| SG (1) | SG11202000660QA (enExample) |
| TW (1) | TWI812632B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202402800A (zh) | 2017-05-01 | 2024-01-16 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體類和使用彼等之方法 |
| IL272227B2 (en) * | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| AU2019272384A1 (en) | 2018-05-23 | 2021-01-07 | Beigene, Ltd. | Anti-OX40 antibodies and methods of use |
| KR102776112B1 (ko) | 2018-09-11 | 2025-03-11 | 아이테오스 벨지움 에스에이 | A2a 억제제로서 싸이오카바메이트 유도체, 이의 약학 조성물 및 항암제와의 조합물 |
| CN113993894B (zh) * | 2019-01-07 | 2024-08-02 | Iteos比利时公司 | 抗tigit抗体 |
| TWI760751B (zh) * | 2019-05-29 | 2022-04-11 | 美商美國禮來大藥廠 | Tigit及pd-1/tigit-結合分子 |
| BR112021022171A2 (pt) * | 2019-06-13 | 2021-12-21 | Green Cross Corp | Anticorpo para tigit, seu uso e método para produzir o mesmo |
| JP7122354B2 (ja) * | 2019-09-24 | 2022-08-19 | 財團法人工業技術研究院 | 抗ｔｉｇｉｔ抗体および使用方法 |
| CN114746446A (zh) * | 2019-11-21 | 2022-07-12 | 百济神州有限公司 | 使用抗ox40抗体与抗tigit抗体组合治疗癌症的方法 |
| US20230057899A1 (en) | 2019-12-05 | 2023-02-23 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
| CN113563470B (zh) * | 2020-04-29 | 2023-02-10 | 广州昂科免疫生物技术有限公司 | 结合tigit抗原的抗体及其制备方法与应用 |
| WO2021258337A1 (en) * | 2020-06-24 | 2021-12-30 | Huahui Health Ltd. | Human monoclonal antibodies against tigit for immune related diseases |
| CA3194641A1 (en) * | 2020-10-26 | 2022-05-05 | Akeso Biopharma, Inc. | Anti-tigit antibody, and pharmaceutical composition and use thereof |
| WO2022111612A1 (zh) * | 2020-11-26 | 2022-06-02 | 信达生物制药(苏州)有限公司 | 包含抗tigit/pd-1双特异性抗体的制剂及其制备方法和用途 |
| CN114539418A (zh) * | 2020-11-26 | 2022-05-27 | 上海华奥泰生物药业股份有限公司 | 双特异性抗体及其用途 |
| EP4293045A4 (en) * | 2021-01-14 | 2024-12-11 | Shanghai Junshi Biosciences Co., Ltd. | PHARMACEUTICAL COMPOSITION OF ANTI-TIGIT ANTIBODY AND ITS APPLICATION |
| CN114790241B (zh) * | 2021-01-26 | 2024-12-13 | 北京免疫方舟医药科技有限公司 | 抗tigit抗体及其应用 |
| CN112794909B (zh) * | 2021-02-04 | 2022-06-14 | 广州爱思迈生物医药科技有限公司 | 一种抗tigit单克隆抗体及其应用 |
| WO2022179567A1 (zh) * | 2021-02-24 | 2022-09-01 | 克莱格医学有限公司 | Tigit工程化细胞及其组合物 |
| CN114984227A (zh) * | 2021-03-02 | 2022-09-02 | 百奥泰生物制药股份有限公司 | 抗tigit抗体在联合用药中的应用 |
| CN114989300A (zh) * | 2021-03-02 | 2022-09-02 | 百奥泰生物制药股份有限公司 | 抗tigit抗体在治疗肿瘤或癌症中的应用 |
| CN113150156B (zh) * | 2021-04-22 | 2022-06-07 | 浙江博锐生物制药有限公司 | 抗tigit抗体及其用途 |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| CA3219603A1 (en) * | 2021-05-10 | 2022-11-17 | Medimabbio Inc. | Anti-tigit antibodies and use thereof |
| EP4386003A1 (en) * | 2021-08-09 | 2024-06-19 | Biotheus Inc. | Anti-tigit antibody and use thereof |
| CN115838424A (zh) * | 2021-09-22 | 2023-03-24 | 上海康岱生物医药技术股份有限公司 | 靶向tigit的单克隆抗体 |
| CN115925945A (zh) * | 2021-09-24 | 2023-04-07 | 广东菲鹏制药股份有限公司 | 抗tigit人源化抗体或其抗原结合片段及其应用 |
| CN116135884A (zh) * | 2021-11-17 | 2023-05-19 | 普米斯生物技术(珠海)有限公司 | 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途 |
| CN116143923B (zh) * | 2022-12-30 | 2025-11-11 | 合肥天港免疫药物有限公司 | 高亲和力tigit抗体及其应用 |
| WO2024251140A1 (en) * | 2023-06-06 | 2024-12-12 | Wuxi Biologics (Shanghai) Co., Ltd. | Anti-tigit antibodies and uses thereof |
| CN119285774A (zh) * | 2023-10-11 | 2025-01-10 | 首都医科大学附属北京胸科医院 | 抗人tigit单克隆抗体tigit-m007或其功能性片段及其应用 |
| CN119431580B (zh) * | 2024-09-29 | 2025-11-18 | 上海百英生物科技股份有限公司 | 一种抗人tigit单克隆抗体及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| WO2003072035A2 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| ES2357505T3 (es) | 2002-09-11 | 2011-04-27 | Genentech, Inc. | Composición y procedimientos novedosos para el tratamiento de enfermedades inmunorelacionadas. |
| CN1835975B (zh) * | 2003-08-13 | 2012-11-21 | 辉瑞产品公司 | 经修饰的人类igf-1r抗体 |
| US20070054360A1 (en) | 2005-05-12 | 2007-03-08 | Zeren Gao | Compositions and methods for modulating immune responses |
| EP1963534A2 (en) | 2005-12-19 | 2008-09-03 | Genizon Biosciences Inc. | Genemap of the human gene associated with crohn's disease |
| CA2697193C (en) | 2007-09-14 | 2017-06-06 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| MX2010011088A (es) | 2008-04-09 | 2010-11-05 | Genentech Inc | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. |
| CA2755782A1 (en) | 2009-03-18 | 2010-09-23 | Simon Barry | Peptidase inhibitor 16 (pi16) as a biomarker for regulatory t 9treg) cells and uses therefor |
| EP2388336A1 (en) | 2010-05-19 | 2011-11-23 | Signature Diagnostics AG | Method and kits for diagnosing colorectal cancer |
| US8822642B2 (en) | 2010-06-09 | 2014-09-02 | Zymogenetics, Inc. | Dimeric fusion proteins and related compositions and methods |
| WO2012009568A2 (en) | 2010-07-16 | 2012-01-19 | Adimab, Llc | Antibody libraries |
| DE102011005235B4 (de) | 2011-03-08 | 2017-05-24 | Sirs-Lab Gmbh | Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| WO2013184912A2 (en) | 2012-06-06 | 2013-12-12 | Oncomed Pharmaceuticals, Inc. | Binding agents that modulate the hippo pathway and uses thereof |
| DK2925350T3 (da) | 2012-12-03 | 2019-05-13 | Bristol Myers Squibb Co | Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner |
| HK1221908A1 (zh) | 2013-04-29 | 2017-06-16 | Adimab, Llc | 多特异(polyspecificity)试剂，其制备方法和用途 |
| DK3021869T3 (da) * | 2013-07-16 | 2020-09-21 | Hoffmann La Roche | Fremgangsmåder til behandling af cancer ved anvendelse af PD-1-aksebindende antagonister og TIGIT-hæmmere |
| WO2016011264A1 (en) | 2014-07-16 | 2016-01-21 | Genentech, Inc. | Methods of treating cancer using tigit inhibitors and anti-cancer agents |
| KR102050082B1 (ko) * | 2014-08-19 | 2019-11-29 | 머크 샤프 앤드 돔 코포레이션 | 항-tigit 항체 |
| RU2017119428A (ru) | 2014-11-06 | 2018-12-06 | Дженентек, Инк. | Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit |
| SG10202006538TA (en) * | 2014-12-23 | 2020-08-28 | Bristol Myers Squibb Co | Antibodies to tigit |
| TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| US10766957B2 (en) * | 2015-08-14 | 2020-09-08 | Merck Sharp & Dohme Corp | Anti-TIGIT antibodies |
| EP3353210B8 (en) | 2015-09-25 | 2024-12-18 | F. Hoffmann-La Roche AG | Anti-tigit antibodies and methods of use |
| SG10201912736UA (en) | 2015-10-01 | 2020-02-27 | Potenza Therapeutics Inc | Anti-tigit antigen-binding proteins and methods of use thereof |
| IL261188B (en) * | 2016-03-04 | 2022-08-01 | Jn Biosciences Llc | An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues |
| CN109071656B (zh) | 2017-01-05 | 2021-05-18 | 璟尚生物制药公司 | 检查点调节物拮抗剂 |
| MA47694A (fr) * | 2017-02-28 | 2021-05-19 | Seagen Inc | Anticorps anti-tigit |
| TW202402800A (zh) | 2017-05-01 | 2024-01-16 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體類和使用彼等之方法 |
| WO2018229163A1 (en) * | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| IL272227B2 (en) | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| SG11202011461TA (en) * | 2018-06-01 | 2020-12-30 | Compugen Ltd | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
| CN113993894B (zh) * | 2019-01-07 | 2024-08-02 | Iteos比利时公司 | 抗tigit抗体 |
-
2018
- 2018-07-25 IL IL272227A patent/IL272227B2/en unknown
- 2018-07-26 EP EP20173561.0A patent/EP3719040A1/en active Pending
- 2018-07-26 CN CN201880048693.8A patent/CN110997720B/zh active Active
- 2018-07-26 JP JP2020527852A patent/JP7366897B2/ja active Active
- 2018-07-26 KR KR1020207005664A patent/KR102731476B1/ko active Active
- 2018-07-26 ES ES18750302T patent/ES2812236T3/es active Active
- 2018-07-26 MX MX2020000960A patent/MX2020000960A/es unknown
- 2018-07-26 CA CA3070791A patent/CA3070791A1/en active Pending
- 2018-07-26 SG SG11202000660QA patent/SG11202000660QA/en unknown
- 2018-07-26 CN CN202411294417.3A patent/CN119841950A/zh active Pending
- 2018-07-26 AU AU2018306463A patent/AU2018306463B2/en active Active
- 2018-07-26 US US16/634,506 patent/US20200407445A1/en not_active Abandoned
- 2018-07-26 BR BR112020001499-0A patent/BR112020001499A2/pt not_active Application Discontinuation
- 2018-07-26 EP EP18750302.4A patent/EP3484925B1/en active Active
- 2018-07-27 AR ARP180102114A patent/AR112768A1/es unknown
- 2018-07-27 TW TW107126050A patent/TWI812632B/zh active
- 2018-10-12 US US16/159,506 patent/US10329349B2/en active Active
-
2019
- 2019-05-15 US US16/413,557 patent/US11439705B2/en active Active
-
2020
- 2020-01-24 MX MX2024000742A patent/MX2024000742A/es unknown
-
2022
- 2022-07-25 US US17/872,494 patent/US20230190931A1/en active Pending
- 2022-09-16 US US17/946,158 patent/US20230181731A1/en not_active Abandoned
-
2023
- 2023-07-28 JP JP2023123773A patent/JP2023153911A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528768A5 (enExample) | ||
| JP2022177090A5 (enExample) | ||
| JP2020079252A5 (enExample) | ||
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| IL312961A (en) | Anti-tmprss2 antibodies and antigen-binding fragments | |
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| CN115003333A (zh) | Pvrig结合蛋白及其医药用途 | |
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| JP2018502060A5 (enExample) | ||
| RU2009136913A (ru) | Биспецифические связывающие агенты с межвидовой специфичностью | |
| HRP20220637T1 (hr) | Protutijela anti-komplementa c1s i njihova upotreba | |
| RU2013130609A (ru) | Гуманизированные антитела к liv-1 и их применение для лечения рака | |
| JPWO2019246514A5 (enExample) | ||
| RU2011101969A (ru) | Антитела к человеческому интерлейкину-20 | |
| CN101535344A (zh) | 新型抗增殖抗体 | |
| RU2014153440A (ru) | Антитела против cd26 и их применение | |
| US12173081B2 (en) | CD19/CD38 multispecific antibodies | |
| RU2008138541A (ru) | Способы разрушения клеток с использованием эффекторных функций анти-epha4 антител | |
| RU2015108797A (ru) | Антитела к jagged и способы их применения перекрестная ссылка на родственные заявки | |
| JP2019528046A5 (enExample) | ||
| RU2019103991A (ru) | Анти-il-22r-антитела | |
| IL277899B2 (en) | Methods and preparations for treating yellow fever | |
| JP2018529672A5 (enExample) | ||
| RU2020128108A (ru) | Антитело против cd25 для опухоль-специфической клеточной деплеции | |
| JPWO2020144178A5 (enExample) |